TY - JOUR
T1 - Multicenter trial of L-Deprenylin Parkinson disease
AU - Ruggieri, S.
AU - Denaro, A.
AU - Meco, G.
AU - Carta, A.
AU - Stocchi, F.
AU - Agnoli, A.
PY - 1986/2
Y1 - 1986/2
N2 - A multicenter trial was conducted at 9 Neurology Departements to evaluate the action of L-Deprenyl, a specific monoamine oxidase-B inhibitor, combined with L-Dopa in the treatment of Parkinson disease. In all, 76 patients were treated, 33 women and 43 men, on stable treatment with L-Dopa+aromatic decarboxylase inhibitors (DI) for at least 6 months. After a 50% reduction of the L-Dopa dose, all received L-Deprenyl 5 mg twice daily for 35 day. The combined treatment resulted in a definite improvement in rigidity, bradykinesia and, most of all, tremor. Further, at the end of treatment fewer patients had depressive symptoms and the total daily number of hours of wellbeing and normal movement increased. 12 patients presented modest side effects, in no case serious enough to warrant suspension of treatment. The trial shows that with the L-Deprenyl+L-Dopa combination the dose of L-Dopa needed to control the disease can be drastically reduced.
AB - A multicenter trial was conducted at 9 Neurology Departements to evaluate the action of L-Deprenyl, a specific monoamine oxidase-B inhibitor, combined with L-Dopa in the treatment of Parkinson disease. In all, 76 patients were treated, 33 women and 43 men, on stable treatment with L-Dopa+aromatic decarboxylase inhibitors (DI) for at least 6 months. After a 50% reduction of the L-Dopa dose, all received L-Deprenyl 5 mg twice daily for 35 day. The combined treatment resulted in a definite improvement in rigidity, bradykinesia and, most of all, tremor. Further, at the end of treatment fewer patients had depressive symptoms and the total daily number of hours of wellbeing and normal movement increased. 12 patients presented modest side effects, in no case serious enough to warrant suspension of treatment. The trial shows that with the L-Deprenyl+L-Dopa combination the dose of L-Dopa needed to control the disease can be drastically reduced.
KW - L-Deprenyl
KW - Parkinson disease
UR - http://www.scopus.com/inward/record.url?scp=0022587669&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022587669&partnerID=8YFLogxK
U2 - 10.1007/BF02230431
DO - 10.1007/BF02230431
M3 - Article
C2 - 3082793
AN - SCOPUS:0022587669
VL - 7
SP - 133
EP - 137
JO - Italian Journal of Neurological Sciences
JF - Italian Journal of Neurological Sciences
SN - 0392-0461
IS - 1
ER -